Physician profile
Ellen Y Wang
NPI 1619288065
$3,594.21
in general payments reported to CMS, 2019-2025
22 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $13.71 · 2021: $897 · 2022: $805 · 2023: $544 · 2024: $662 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,086.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $452.05 | 2019-2025 | |
| Pfizer INC. | $302.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.85 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $162.03 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $150.11 | 2022 | |
| Medtronic, INC. | $148.56 | 2021-2022 | |
| Amgen INC. | $129.81 | 2023-2025 | Repatha, Repatha |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Cvrx, INC. | $118.84 | 2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $117.79 | 2023-2025 | |
| Edwards Lifesciences Corporation | $105.81 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $93.62 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $78.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $75.18 | 2024-2025 | Farxiga, Wainua |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $56.03 | 2022-2024 | Uptravi |
| Esperion Therapeutics, INC. | $55.59 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $33.91 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.65 | 2022-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $18.98 | 2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $14.90 | 2025 | Onpattro |
| Infobionic, INC | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.